Heron Therapeutics (HRTX) CEO exercises 84,810 RSUs into common shares
Rhea-AI Filing Summary
Heron Therapeutics CEO Craig A. Collard exercised previously granted restricted stock units into common stock in late July 2026. On July 30 he converted 50,021 RSUs, and on July 31 he converted 34,789 RSUs, each on a one-for-one basis at a stated price of $0.00 per share. The RSUs vest in 16 equal quarterly installments beginning one quarter after their respective grant dates in January 2025 and January 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 84,810 shares
Net Buy
4 txns
Insider
Collard Craig A
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3 | 34,789 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 34,789 | -- | -- |
| Exercise | Restricted Stock Units F2 | 50,021 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 50,021 | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 1,048,181 shares (Direct);
Common Stock — 856,492 shares (Direct)
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.
- F3. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
Key Figures
RSUs converted on 2026-07-30: 50,021 shares
RSUs converted on 2026-07-31: 34,789 shares
Total RSU conversions: 84,810 shares
+2 more
5 metrics
RSUs converted on 2026-07-30
50,021 shares
Restricted stock units converted into common stock on July 30, 2026
RSUs converted on 2026-07-31
34,789 shares
Restricted stock units converted into common stock on July 31, 2026
Total RSU conversions
84,810 shares
Aggregate restricted stock units converted into common stock across both July 2026 transactions
RSU grant size
800,337 RSUs
Grant awarded January 30, 2026, vesting in 16 equal quarterly installments
Exercise/Conversion price
$0.00 per share
Stated price for the RSU conversions into common stock
Key Terms
Restricted Stock Units, contingent right, time-based vesting schedule, Date of Grant
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of common stock"
time-based vesting schedule financial
"RSUs which vest upon the following time-based vesting schedule"
Date of Grant financial
"On January 30, 2026 (the "Date of Grant"), the Reporting Person"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Heron Therapeutics (HRTX) CEO Craig A. Collard report?
Craig A. Collard reported two RSU conversions into common stock. On July 30, 2026, 50,021 restricted stock units converted, and on July 31, 2026, another 34,789 RSUs converted, all on a one-for-one basis into common shares at $0.00 per share.
How many Heron Therapeutics (HRTX) RSUs did the CEO convert and at what price?
Across both transactions, Craig A. Collard converted 84,810 restricted stock units into common stock. Each RSU represented one share, and the stated exercise or conversion price was $0.00 per share, indicating no cash price was paid per share in these conversions.
What are the vesting terms of Craig A. Collard’s 800,337 RSU grant at Heron Therapeutics (HRTX)?
On January 30, 2026, Craig A. Collard was granted 800,337 RSUs. These restricted stock units vest under a time-based vesting schedule in 16 equal quarterly installments, with vesting beginning one quarter after the January 30, 2026 grant date.
How do the earlier Heron Therapeutics (HRTX) RSUs held by the CEO vest?
A separate tranche of restricted stock units vests in 16 equal installments, beginning one quarter after the January 31, 2025 grant date. Each vested restricted stock unit represents a contingent right to receive one share of Heron Therapeutics common stock.
Were Craig A. Collard’s Heron Therapeutics (HRTX) RSU transactions under a Rule 10b5-1 trading plan?
The reported RSU conversions were not indicated as being executed under a Rule 10b5-1 trading plan. The regulatory checkbox for Rule 10b5-1 plan status was not affirmed, so the transactions are not reported as pre-arranged under such a plan.
What does each RSU reported by Heron Therapeutics (HRTX) represent for the CEO?
Each restricted stock unit reported for Craig A. Collard represents a contingent right to receive one share of Heron Therapeutics common stock. When an RSU vests and is converted, the CEO receives one share for each RSU on a one-for-one basis.